In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Update on USFDA Inspection at Company''s manufacturing facility in Virgonagar, Bengaluru, India ...

The logo of Google LLC is shown on a building in ... Google’s Chief People Officer, Fiona Cicconi, informed employees that the company would no longer maintain its ‘’aspirational hiring ...

Finance Ministry directs employees to not use of AI tools like ChatGPT, DeepSeek - Here’s the reason why. (Image: Getty) India’s finance ministry has advised its employees against using AI ...

Top Indian drugmaker Sun Pharma's Q3 profit beats estimates on strong local sales January 31, 2025 Cipla , one of ... and Nicotinell acquisition, the company said on Tuesday.

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Earnings Today: Several companies are set to announce their quarterly earnings on January 28, including Bajaj Auto, BHEL, Bosch, CG Power and Industrial Solutions, Cipla, Colgate Palmolive, CSB Bank, ...

Cipla's stock settled 2.2% higher at ₹1,427 on Tuesday on the National Stock Exchange. The company expects to launch its breast cancer drug Abraxane, which was originally slated for a rollout in ...

Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.